The Emerging Role of HER2 (ERBB2) Mutations in NSCLC

The Emerging Role of HER2 (ERBB2) Mutations in NSCLC

The Emerging Role of HER2 (ERBB2) Mutations in NSCLC

Did you know that HER2 is now an emerging biomarker for NSCLC? Tune in to find out what’s on the horizon for your practice and your patients.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Since the release of this activity, the FDA has approved the use of trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations, as determined by an FDA-approved test, for those who have received prior systemic therapy. Visit the FDA statement dated August 11, 2022 to learn more.

    HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Dr. Lyudmila Bazhenova and Dr. Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Lyudmila A. Bazhenova, MD
    Professor of Clinical Medicine
    UCSD Moores Cancer Center
    La Jolla, CA

    Research: BeyondSpring
    Consulting Fees: AstraZeneca, Bayer, Blueprint, BMS, Boehringer Ingelheim, Daiichi, Genentech, Janssen, Merck, Mirati, NEUVOGEN, Novartis, ORIC, Regeneron, Sanofi, Takeda, Turning Point Therapeutics

    Benjamin Levy, MD
    Associate Professor
    Johns Hopkins Sibley Memorial Hospital
    Washington, DC

    Consulting Fees: Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Janssen, Merck, Mirati, Novartis, Pfizer, Takeda

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Anita Misra-Press has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Stephanie Wenick, MPhil has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the different types of HER2 alterations/expression, including the significance of HER2 mutations in patients with NSCLC and its overall effect on treatment
    • Evaluate clinical efficacy and safety data on the use of HER2-directed therapies in patients with NSCLC
  • Target Audience

    This activity is designed to meet the educational needs of community and academic medical oncologists and pathologists, pulmonologists, oncology nurse practitioners, physician assistants, oncology nurses, oncology pharmacists, and other HCPs treating patients with lung cancer.

  • Accreditation and Credit Designation Statements

     In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

     Global Learning Collaborative (GLC) designates this Enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until 4/19/2023 PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free